Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Non-Hodgkin's Lymphoma

Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study

Bone Marrow Transplantation volume 30, pages 229–234 (2002)Cite this article

Abstract

The role of allogeneic BMT for follicular lymphoma remains to be established. From 1995 to 2000, 16 patients with follicular lymphoma underwent allogeneic BMT at our center. At the time of transplantation, two patients were in complete remission, 11 in partial remission and three had refractory disease. Fourteen patients were transplanted using a standard myeloablative conditioning regimen and two a nonmyeloablative conditioning regimen. With a median follow-up of 1184 days (range 403–1999 days) after BMT, 11 patients were alive, whereas five died of transplant-related mortality. Eight patients remained in CR 284+ to 1022+ days (median 560+ days) after BMT. Two patients relapsed 63 and 1073 days after BMT. They achieved a further complete remission after salvage treatment and remained alive 403 and 1224 days after BMT, respectively. One patient with autologous reconstitution had never been in CR after BMT. He was retreated with salvage chemotherapy but only achieved CR with subsequent rituximab treatment and was still alive, 1999 days after transplantation. The estimated 2-year overall survival and event-free survival rates were 68% and 55%, respectively. Age greater than 37 years at diagnosis, positive recipient CMV serology and ECOG performance status ⩾1 at diagnosis were associated with shorter overall survival (P = 0.05, P = 0.009 and P = 0.03, respectively). Ann Arbor III–IV stage at diagnosis was associated with shorter event-free survival (P < 0.04). Allogeneic BMT seems to be effective for patients with follicular lymphoma. However, the relatively high rate of early transplant-related mortality emphasizes the need to define indications and use prospective protocols involving a less toxic transplant procedure.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Horning SJ . Treatment approaches to the low-grade lymphomas Blood 1994 83: 881 884

    CAS  PubMed  Google Scholar 

  2. Romaguera JE, McLaughlin P, North L et al. Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model J Clin Oncol 1991 9: 762 769

    Article  CAS  PubMed  Google Scholar 

  3. Brice P, Bastion Y, Lepage E et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alpha: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 1997 15: 1110 1117

    Article  CAS  PubMed  Google Scholar 

  4. Solal-Celigny P, Lepage E, Brousse N et al. Doxorubicin-containing regimen with or without interferon alpha-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial J Clin Oncol 1998 16: 2332 2338

    Article  CAS  PubMed  Google Scholar 

  5. Solal-Celigny P, Brice P, Brousse N et al. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol 1996 14: 514 519

    Article  CAS  PubMed  Google Scholar 

  6. Lazzarino M, Orlandi E, Montillo M et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma Ann Oncol 1999 10: 59 64

    Article  CAS  PubMed  Google Scholar 

  7. McLaughlin P, Hagemeister F, Romaguera J et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma J Clin Oncol 1996 14: 1262 1268

    Article  CAS  PubMed  Google Scholar 

  8. Armitage JO . Bone marrow transplantation for indolent lymphomas Semin Oncol 1993 20: 136 142

    CAS  PubMed  Google Scholar 

  9. Freedman AS, Ritz J, Neuberg D et al. Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma Blood 1991 77: 2524 2529

    CAS  PubMed  Google Scholar 

  10. Maloney D, Grillo-Lopez A, White C et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood 1997 90: 2188 2195

    CAS  PubMed  Google Scholar 

  11. McLaughlin P, Grillo-Lopez A, Link B et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program J Clin Oncol 1998 16: 2825 2833

    Article  CAS  PubMed  Google Scholar 

  12. Aviles A, Talavera A, Diaz-Maqueo J et al. Evaluation on a six-dose treatment of anti-CD20 monoclonal antibody in patients with refractory follicular lymphoma Cancer Biother Radiopharm 2001 16: 159 162

    Article  CAS  PubMed  Google Scholar 

  13. Colombat P, Salles G, Brousse N et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation Blood 2001 97: 101 106

    Article  CAS  PubMed  Google Scholar 

  14. Van Besien K, de Lima M, Giralt S et al. Management of lymphoma recurrence after allogeneic transplantation: the relevance of graft-versus-lymphoma effect Bone Marrow Transplant 1997 19: 977 982

    Article  CAS  PubMed  Google Scholar 

  15. Ratanatharathorn V, Uberti J, Karanes C et al. Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma Blood 1994 84: 1050 1055

    CAS  PubMed  Google Scholar 

  16. Van Besien KW, Khouri IF, Giralt SA et al. Allogeneic bone marrow transplantation for refractory and recurrent low-grade lymphoma: the case for aggressive management J Clin Oncol 1995 13: 1096 1102

    Article  CAS  PubMed  Google Scholar 

  17. Verdonck L, Dekker A, Lokhorst H et al. Allogeneic versus autologous bone marrow transplantation for refractory and recurrent low-grade non-Hodgkin's lymphoma Blood 1997 90: 4201 4205

    CAS  PubMed  Google Scholar 

  18. Van Besien K, Sobocinski K, Rowlings P et al. Allogeneic bone marrow transplantation for low-grade lymphoma Blood 1998 92: 1832 1836

    CAS  PubMed  Google Scholar 

  19. Attal M, Socié G, Molina L . Allogeneic bone marrow transplantation for refractory and recurrent follicular lymphoma: a case-matched analysis with autologous transplantation from the French bone marrow transplantation group registery data (abstract) Blood 1997 93: 1120a

    Google Scholar 

  20. Stein R, Greer J, Goodman S et al. High-dose therapy with autologous or allogeneic transplantation as salvage therapy for small cleaved cell lymphoma of follicular center cell origin Bone Marrow Transplant 1999 23: 227 233

    Article  CAS  PubMed  Google Scholar 

  21. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hemapoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting – Airlie House, Virginia, November 1997 J Clin Oncol 1999 17: 3835 3849

    Article  CAS  PubMed  Google Scholar 

  22. Carbone PP, Kaplan HS, Musshoff K et al. Report of the Committee on Hodgkin's Disease Staging Classification Cancer Res 1971 31: 1860 1861

    CAS  PubMed  Google Scholar 

  23. McDonald GB, Sharma P, Matthews DE et al. Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence, and predisposing factors Hepatology 1984 4: 116 122

    Article  CAS  PubMed  Google Scholar 

  24. McDonald GB, Hinds MS, Fisher LD et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients Ann Intern Med 1993 118: 255 267

    Article  CAS  PubMed  Google Scholar 

  25. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors Transplantation 1974 18: 295 304

    Article  CAS  PubMed  Google Scholar 

  26. Kaplan E, Meier P . Non parametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457 481

    Article  Google Scholar 

  27. Peto R, Peto J . Asymptotically efficient rank invariant test procedures J R Stat Soc 1972 135: 185 206

    Google Scholar 

  28. Yakoub-Agha I, de La Salmoniere P, Ribaud P et al. Allogeneic bone marrow transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia: a long-term study of 70 patients – report of the French society of bone marrow transplantation J Clin Oncol 2000 18: 963 971

    Article  CAS  PubMed  Google Scholar 

  29. Dann E, Daugherty C, Larson R . Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma Bone Marrow Transplant 1997 20: 369 374

    Article  CAS  PubMed  Google Scholar 

  30. Bernard M, Dauriac C, Drenou B, Leberre C, Branger B et al. Long-term follow-up of allogeneic bone marrow transplantation in patients with poor prognosis non-Hodgkin's lymphoma Bone Marrow Transplant 1999 23: 329 333

    Article  CAS  PubMed  Google Scholar 

  31. Weisdorf D, Andersen J, Glick J, Oken M . Survival after relapse of low-grade non-Hodgkin's lymphoma: implications for marrow transplantation J Clin Oncol 1992 10: 942 947

    Article  CAS  PubMed  Google Scholar 

  32. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756 763

    CAS  PubMed  Google Scholar 

  33. Champlin R, Khouri I, Kornblau S et al. Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus- malignancy Curr Opin Oncol 1999 11: 87 95

    Article  CAS  PubMed  Google Scholar 

  34. Champlin R, Khouri I, Anderlini P et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation Bone Marrow Transplant 2001 27: (Suppl. 2) S13 22

    Article  PubMed  Google Scholar 

  35. Sastry P . Adoptive immunotherapy for cutaneous T-cell lymphomas Med Hypotheses 1999 52: 353 354

    Article  CAS  PubMed  Google Scholar 

  36. Porter D, Antin J . The graft-versus-leukemia effects of allogeneic cell therapy Annu Rev Med 1999 50: 369 386

    Article  CAS  PubMed  Google Scholar 

  37. Hale G, Jacobs P, Wood L et al. CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells Bone Marrow Transplant 2000 26: 69 76

    Article  CAS  PubMed  Google Scholar 

  38. Mackinnon S, Papadopoulos EB, Carabasi MH et al. Adoptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation: separation of graft-versus-leukemia responses from graft-versus-host disease Blood 1995 86: 1261 1268

    CAS  PubMed  Google Scholar 

  39. Giralt S, Hester J, Huh Y et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation Blood 1995 86: 4337 4343

    CAS  PubMed  Google Scholar 

  40. Bonini C, Ferrari G, Verzeletti S et al. HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia Science 1997 276: 1719 1724

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unité de Greffes de moelle, Services des Maladies du Sang, CHRU, Lille, France

    I Yakoub-Agha, A Fawaz, O Folliot, G Guillerm, B Quesnel, P Fenaux, F Bauters, JP Jouet & F Morschhauser

Authors
  1. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A Fawaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. O Folliot
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G Guillerm
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B Quesnel
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. P Fenaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. F Bauters
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. JP Jouet
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. F Morschhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yakoub-Agha, I., Fawaz, A., Folliot, O. et al. Allogeneic bone marrow transplantation in patients with follicular lymphoma: a single center study. Bone Marrow Transplant 30, 229–234 (2002). https://doi.org/10.1038/sj.bmt.1703625

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703625

Keywords

This article is cited by

Search

Advanced search

Quick links